Key result
The Sentry bioconvertible IVC filter achieved successful conversion in 95.7% of patients at 6 months and 96.4% at 12 months, with no cases of symptomatic pulmonary embolism through 12 months.
Why the study?
Retrievable IVC filters designed for temporary PE protection are frequently not removed, have time-dependent complications, and risk retrieval failure.
Does the Sentry bioconvertible IVC filter prevent pulmonary embolism and successfully bioconvert in patients with DVT/PE and contraindications to anticoagulation?
Population
129 patients with documented DVT or PE, or at temporary risk, with anticoagulation contraindications
Comparison
Sentry bioconvertible IVC filter
Design
Multicenter investigational-device-exemption pivotal trial
Follow-up
12 months
Authors
Loading...
Bioconvertible IVC filter may enable transient PE protection without permanent implantation; leaves open safety and efficacy in high-risk patients.
Does the Sentry bioconvertible IVC filter prevent pulmonary embolism and successfully bioconvert in patients with DVT/PE and contraindications to anticoagulation?
The Sentry bioconvertible IVC filter provides temporary PE protection with high rates of successful bioconversion, potentially avoiding complications associated with unretrieved conventional filters.
Dake et al. (2019) studied Deep vein thrombosis or pulmonary embolism (n=129). Sentry bioconvertible inferior vena cava filter was evaluated on Successful filter conversion at 6 months. The Sentry bioconvertible IVC filter achieved successful conversion in 95.7% of patients at 6 months and 96.4% at 12 months, with no cases of symptomatic pulmonary embolism through 12 months.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: